Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk group.

abstract：:Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12-15 months. Currently, several clinical trials of dose-dense temozolomide regimen or molecular-targ...

journal_title：Expert review of anticancer therapy

authors： Shirai K,Chakravarti A

更新日期：2011-12-01 00:00:00

abstract：:Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of these patients and is considered the standard of care. Nevertheless, 40-50% of patients have impaired renal function that p...

journal_title：Expert review of anticancer therapy

authors： Bournakis E,Dimopoulos MA,Bamias A

更新日期：2011-06-01 00:00:00

abstract：:The association between venous thromboembolism (VTE) and malignancy was first recognized more than 135 years ago. Since then, a markedly increased incidence of VTE has been found in patients with malignant disease. Numerous clinical studies have demonstrated that malignancy or its treatment are major risk factors for ...

journal_title：Expert review of anticancer therapy

authors： Gao S,Escalante C

更新日期：2004-04-01 00:00:00

abstract：:Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

journal_title：Expert review of anticancer therapy

authors： Hussein MR,Baidas S

更新日期：2002-10-01 00:00:00

abstract：:Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

journal_title：Expert review of anticancer therapy

authors： Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

更新日期：2006-06-01 00:00:00

abstract：:Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...

journal_title：Expert review of anticancer therapy

authors： Sathornsumetee S,Rich JN

更新日期：2006-07-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is the most common primary brain malignancy. The current standard of therapy consists of surgical resection followed by concurrent chemoradiotherapy with temozolomide. Despite steady advances in all therapeutic modalities, clinical improvements have been slow and the prognosis remains poo...

journal_title：Expert review of anticancer therapy

authors： Wardak Z,Choe KS

更新日期：2013-11-01 00:00:00

abstract：:The incidence of colorectal cancers is rising worldwide and pulmonary metastases were seen in approximately 10-15% of all patients. Surgical metastasectomy is a widely accepted procedure in selected patients and is considered as the only curative option in patients with secondary pulmonary malignancy. But surgical res...

journal_title：Expert review of anticancer therapy

authors： Limmer S,Unger L

更新日期：2011-10-01 00:00:00

abstract：:Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

journal_title：Expert review of anticancer therapy

authors： Martin-Liberal J,Tirado OM,García del Muro X

更新日期：2015-03-01 00:00:00

abstract：:Current targeted strategies for cancer focus on the blockade of growth factor receptors and the inhibition of angiogenesis. The VEGF pathway has become an attractive target in multiple malignancies, including lung cancer. Bevacizumab, a monoclonal antibody against VEGF, increased survival in non-small-cell lung cancer...

journal_title：Expert review of anticancer therapy

authors： Planchard D

更新日期：2011-08-01 00:00:00

abstract：:Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...

journal_title：Expert review of anticancer therapy

authors： Vijayamurugan N,Bakhshi S

更新日期：2014-02-01 00:00:00

abstract：:Genomics has generated a wealth of data that is now being used to identify additional molecular alterations associated with cancer development. Mapping these alterations in the cancer genome is a critical first step in dissecting oncological pathways. There are two ways in which cancer research has changed in recent y...

journal_title：Expert review of anticancer therapy

authors： Sakatani T,Onyango P

更新日期：2003-12-01 00:00:00

abstract：:As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...

journal_title：Expert review of anticancer therapy

authors： Batus M,Fidler MJ,Bonomi PD

更新日期：2010-10-01 00:00:00

abstract：INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O,Oweira H,Giryes A

更新日期：2018-12-01 00:00:00

abstract：:Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

journal_title：Expert review of anticancer therapy

authors： Ward JF,Blute ML

更新日期：2003-04-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is critical for tumor growth, proliferation and metastasis with the crucial role of Vascular Endothelial Growth factor (VEGF) pathway. Ramucirumab is a monoclonal antibody that specifically targets the extracellular domain of Vascular Endothelial Growth Factor Receptor 2. Areas covered: We per...

journal_title：Expert review of anticancer therapy

authors： Paulus V,Avrillon V,Pérol M

更新日期：2016-11-01 00:00:00

abstract：:Ductal carcinoma in situ is a premalignant disease of the breast with a rapidly rising incidence. For women with localized ductal carcinoma in situ, randomized trials have shown that radiation therapy following conservative surgery lowers the relative risk of progression to invasive disease by 60%. Therefore, followin...

journal_title：Expert review of anticancer therapy

authors： Smith BD,Smith GL,Buchholz TA

更新日期：2008-03-01 00:00:00

abstract：INTRODUCTION:Tamoxifen, as an essential therapeutic tool in the treatment of estrogen receptor-positive breast cancer, has been available for the past three decades and is currently being utilized as a chemo-preventive agent for patients at high risk for breast carcinoma. However, the induction of chemo-resistance duri...

journal_title：Expert review of anticancer therapy

authors： Merikhian P,Ghadirian R,Farahmand L,Mansouri S,Majidzadeh-A K

更新日期：2017-07-01 00:00:00

abstract：:The treatment of metastatic colorectal cancer has evolved greatly in the last 15 years, involving combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of targeted therapy with bevacizumab, aflibercept, cetuximab, panitumumab and regorafenib in the treatment of m...

journal_title：Expert review of anticancer therapy

authors： Price TJ,Segelov E,Burge M,Haller DG,Tebbutt NC,Karapetis CS,Punt CJ,Pavlakis N,Arnold D,Gibbs P,Shapiro JD

更新日期：2014-12-01 00:00:00

abstract：:Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/o...

journal_title：Expert review of anticancer therapy

authors： Jimeno A,Carducci M

更新日期：2005-06-01 00:00:00

abstract：:Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

journal_title：Expert review of anticancer therapy

authors： Kortmann RD

更新日期：2014-01-01 00:00:00

abstract：:Protein kinase (PK)Calpha and epsilon are rational targets for cancer therapy. However, targeted experimental therapeutics that inhibit PKCalpha or epsilon are unavailable. The authors established recently that covalent modification of an active-site cysteine in human PKCepsilon, Cys452, by small molecules, for exampl...

journal_title：Expert review of anticancer therapy

authors： O'Brian CA,Chu F,Bornmann WG,Maxwell DS

更新日期：2006-02-01 00:00:00

abstract：:Bone metastases are common among patients with stage IV genitourinary cancers. Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event. These events are associated with increased medical expenses and decreased quality of life. Current guidelines recomme...

journal_title：Expert review of anticancer therapy

authors： Mulders PF,Abrahamsson PA,Bukowski RM

更新日期：2010-11-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer deaths with a 5-year survival of 4-6%. Clinical challenges remain to be addressed, since few promising approaches to treat pancreatic cancer have been reported. Here we discuss the potential of a new biotherapeutic agent composed of a lysosomal protein (Saposin C...

journal_title：Expert review of anticancer therapy

authors： Olowokure O,Qi X

更新日期：2014-05-01 00:00:00

abstract：:Rapid malignant proliferation, prior to effective tumor neoangiogenesis, creates a microenvironment around solid cancers, which is predominantly hypoxic and characterized by a high interstitial fluid pressure. Presumably as an adaptive response, tumor cells favor metabolic activity with apparently inefficient energy o...

journal_title：Expert review of anticancer therapy

authors： Abaza M,Luqmani YA

更新日期：2013-10-01 00:00:00

abstract：INTRODUCTION:Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing pla...

journal_title：Expert review of anticancer therapy

authors： Oing C,Seidel C,Bokemeyer C

更新日期：2018-04-01 00:00:00

abstract：:This review summarizes the safety of sorafenib, an oral multikinase inhibitor, focusing on the randomized, placebo-controlled, Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) in renal cell carcinoma, which formed the basis of the approval of sorafenib. Similar to other targeted agents, ...

journal_title：Expert review of anticancer therapy

authors： Hutson TE

更新日期：2007-09-01 00:00:00

abstract：:The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

journal_title：Expert review of anticancer therapy

authors： Espinoza-Delgado I,Childs RW

更新日期：2004-10-01 00:00:00

abstract：:Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

journal_title：Expert review of anticancer therapy

authors： Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

更新日期：2016-01-01 00:00:00

abstract：:Since its introduction almost 40 years ago, intravesical BCG for non-muscle invasive bladder cancer remains one of the most successful cancer immunotherapies. However, up to 40% of patients will progress after BCG therapy and develop invasive bladder cancer. Despite its extensive clinical use, we are only beginning to...

journal_title：Expert review of anticancer therapy

authors： Wu Y,Enting D,Rudman S,Chowdhury S

更新日期：2015-05-01 00:00:00